Daptomycin approved in Japan for the treatment of methicillin-resistant Staphylococcus aureus

References

• KleinESmithDLLaxminarayanRHospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999–2005Emerg Infect Dis2007131840184618258033
   PubMed Web of Science ®Google Scholar
• Japan Nosocomial Infections Surveillance [homepage on the Internet]Japan Nosocomial Infections Surveillance Report Available from: http://www.nih-janis.jp/report/open_report/2010/2/1/ken_Open_Report_201004.pdfAccessed February 7, 2012 Japanese
   Google Scholar
• National Nosocomial Infections SurveillanceNational Nosocomial Infections Surveillance system report, data summary from January 1992 through June 2004Am Infect Control200432470485
   PubMed Web of Science ®Google Scholar
• HowdenBPWardPBCharlesPGTreatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibilityClin Infect Dis20043852152814765345
   PubMed Web of Science ®Google Scholar
• CharlesPGWardPBJohnsonPDHowdenBPGraysonMLClinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureusClin Infect Dis20043844845114727222
   PubMed Web of Science ®Google Scholar
• SteinkrausGWhiteRFriedrichLVancomycin MIC creep in non-vancomycin- intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001–2005J Antimicrob Chemother20076078879417623693
   PubMed Web of Science ®Google Scholar
• TakesueYNakajimaKTakahashiYClinical characteristics of vancomycin minimum inhibitory concentration of 2 μg/mL methicillin-resistant Staphylococcus aureus strains isolated from patients with bacteremiaJ Infect Chemother201117525720625789
   PubMed Web of Science ®Google Scholar
• HagiharaMWiskirchenDEKutiJLNicolauDPIn vitro pharmacodynamics of vancomycin and cefazolin alone and in combination against methicillin-resistant Staphylococcus aureusAntimicrob Agents Chemother20125620220722006007
   PubMed Web of Science ®Google Scholar
• HatanoKYokotaYHanakiHSunakawaKCombined effect of vancomycin or teicoplanin plus a β-lactam antibiotic in mouse infection models caused by β-lactam antibiotic induced vancomycin-resistant MRSA (BIVR)Kansenshogaku Zasshi20068024325016780131
   PubMedGoogle Scholar
• HanakiHYamagushiYEpidemiological investigation of “β-lactam antibiotic induced vancomycin-resistant MRSA (BIVR)”Kansenshogaku Zasshi20037749950412931576
   PubMedGoogle Scholar
• SaitoNAokiKSakuraiTLinezolid treatment for intracranial abscesses caused by methicillin-resistant Staphylococcus aureus – two case reportsNeurol Med Chir201050515517
   PubMed Web of Science ®Google Scholar
• EndimianiABlackfordMDasenbrookECEmergence of linezolid-resistant Staphylococcus aureus after prolonged treatment of cystic fibrosis patients in Cleveland, OhioAntimicrob Agents Chemother2011551684169221263048
   PubMed Web of Science ®Google Scholar
• DumitrescuOBoissetSBadiouCEffect of antibiotics on Staphylococcus aureus producing Panton-Valentine leukocidinAntimicrob Agents Chemother200751515151917242137
   PubMed Web of Science ®Google Scholar
• DumitrescuOBadiouCBesMEffect of antibiotics, alone and in combination, on Panton-Valentine leukocidin production by a Staphylococcus aureus reference strainClin Microbiol Infect20081438438818261123
   PubMed Web of Science ®Google Scholar
• SmithKGemmellCGHunterISThe association between biocide tolerance and the presence or absence of qac genes among hospital-acquired and community-acquired MRSA isolatesJ Antimicrob Chemother200861788417981834
   PubMed Web of Science ®Google Scholar
• YabeSTakanoTHiguchiWMimuraSKurosawaYYamamotoTSpread of the community-acquired methicillin-resistant Staphylococcus aureus USA300 clone among family members in JapanJ Infect Chemother20101637237420628779
   PubMed Web of Science ®Google Scholar
• MoranGJKrishnadasanAGorwitzRJMethicillin-resistant S. aureus infections among patients in the emergency departmentN Engl J Med20061735566667416914702
   PubMed Web of Science ®Google Scholar
• SmallPMChambersHFVancomycin for Staphylococcus aureus endocarditis in intravenous drug usersAntimicrob Agents Chemother199034122712312393284
   PubMed Web of Science ®Google Scholar
• BernareggiABorghiABorgonoviMTeicoplanin metabolism in humansAntimicrob Agents Chemother199236174417491416858
   PubMed Web of Science ®Google Scholar
• HagiharaMUmemuraTKimuraMMoriTHasegawaTMikamoHExploration of optimal teicoplanin dosage based on pharmacokinetic parameters for the treatment of intensive care unit patients infected with methicillin-resistant Staphylococcus aureusJ Infect Chemother2011 [Epub ahead of print.]
   Web of Science ®Google Scholar
• KanazawaNMatsumotoKIkawaKFukamizuTShigemiAYajiKAn initial dosing method for teicoplanin based on the area under the serum concentration time curve required for MRSA eradicationJ Infect Chemother20111729730020714913
   PubMed Web of Science ®Google Scholar
• CavalcantiABGoncalvesARAlmeidaCSBuganoDDSilvaETeicoplanin versus vancomycin for proven or suspected infectionCochrane Database Syst Rev201016CD00702220556772
   PubMed Web of Science ®Google Scholar
• MatsumotoKTakeshitaAIkawaKHigher linezolid exposure and higher frequency of thrombocytopenia in patients with renal dysfunctionInt J Antimicrob Agents20103617918120392606
   PubMed Web of Science ®Google Scholar
• BeibeiLYunCMengliCNanBXuhongYRuiWLinezolid versus vancomycin for the treatment of gram-positive bacterial infections: meta-analysis of randomised controlled trialsInt J Antimicrob Agents20103531219900794
   PubMed Web of Science ®Google Scholar
• TanigawaraYSatoRMoritaKKakuMAikawaNShimizuKPopulation pharmacokinetics of Arbekacin in patients infected with methicillin-resistant Staphylococcus aureusAntimicrob Agents Chemother2006503754376217065621
   PubMed Web of Science ®Google Scholar
• OlesonFBJrBermanCLKirkpatrickJBReganKSLaiJJTallyFPOnce-daily dosing in dogs optimizes daptomycin safetyAntimicrob Agents Chemother2000442948295311036005
   PubMed Web of Science ®Google Scholar
• SilvermanJAPerlmutterNGShapiroHMCorrelation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureusAntimicrob Agents Chemother2003472538254412878516
   PubMed Web of Science ®Google Scholar
• AlbornWEJrAllenNEPrestonDADaptomycin disrupts membrane potential in growing Staphylococcus aureusAntimicrob Agents Chemother199135228222871666494
   PubMed Web of Science ®Google Scholar
• HobbsJKMillerKO’NeillAJChopraIConsequences of daptomycin-mediated membrane damage in Staphylococcus aureusJ Antimicrob Chemother2008621003100818669516
   PubMed Web of Science ®Google Scholar
• KingAPhillipsIThe in vitro activity of daptomycin against 514 Gram-positive aerobic clinical isolatesJ Antimicrob Chemother20014821922311481291
   PubMed Web of Science ®Google Scholar
• GoldsteinEJCitronDMMerriamCVWarrenYATyrrellKLFernandezHTIn vitro activities of daptomycin, vancomycin, quinupristin- dalfopristin, linezolid, and five other antimicrobials against 307 gram-positive anaerobic and 31 Corynebacterium clinical isolatesAntimicrob Agents Chemother20034733734112499210
   PubMed Web of Science ®Google Scholar
• FriedmanLAlderJDSilvermanJAGenetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureusAntimicrob Agents Chemother2006502137214516723576
   PubMed Web of Science ®Google Scholar
• JulianKKosowska-ShickKWhitenerCCharacterization of a daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus strain in a patient with endocarditisAntimicrob Agents Chemother2007513445344817620372
   PubMed Web of Science ®Google Scholar
• MuthaiyanASilvermanJAJayaswalRKTranscriptional profiling reveals that daptomycin induces the Staphylococcus aureus cell wall stress stimulon and genes responsive to membrane depolarizationAntimicrob Agents Chemother20085298099018086846
   PubMed Web of Science ®Google Scholar
• CuiLTominagaENeohHMHiramatsuKCorrelation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureusAntimicrob Agents Chemother2006501079108216495273
   PubMed Web of Science ®Google Scholar
• SakoulasGAlderJThauvin-EliopoulosCMoelleringRCJrEliopoulosGMInduction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycinAntimicrob Agents Chemother2006501581158516569891
   PubMed Web of Science ®Google Scholar
• PatelJBJevittLAHagemanJMcDonaldLCTenoverFCAn association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureusClin Infect Dis2006421652165316652325
   PubMed Web of Science ®Google Scholar
• EisensteinBILipopeptides, focusing on daptomycin, for the treatment of Gram-positive infectionsExpert Opin Investig Drugs20041311591169
   PubMed Web of Science ®Google Scholar
• OlesonFBBermanCLLiAPAn evaluation of the P450 inhibition and induction potential of daptomycin in primary human hepatocytesChem Biol Interact200415013714715535984
   PubMed Web of Science ®Google Scholar
• PertelPEBernardoPFogartyCEffects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community- acquired pneumoniaClin Infect Dis2008461142115118444848
   PubMed Web of Science ®Google Scholar
• SilvermanJAMortinLIVanpraaghADLiTAlderJInhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impactJ Infect Dis20051912149215215898002
   PubMed Web of Science ®Google Scholar
• Cubicin^® Summary of Product Characteristics Available from: http://www.mrsa-cubicin.jp/secure/practitioner_download/index.htmlAccessed February 7, 2012 Japanese
   Google Scholar
• AikawaNKusachiSMikamoHTakesueYWatanabeSToshinariTEfficacy of daptomycin in Japanese patients with MRSA infection in relation to the susceptibility of baseline isolates in a randomized study. Poster A2-020Chicago, IL51st Interscience Conference on Antimicrobial Agents and ChemotherapyAmerican Society for Microbiology2011
   Google Scholar
• Clinical and Laboratory Standards InstituteMethods for dilution antimicrobial susceptibility tests for bacteria that grow aerobicallyApproved StandardsEighth Edition CLSI document M07-A8Wayne, PAClinical and Laboratory Standards Institute2009
   Google Scholar
• FowlerVGJrBoucherHWCoreyGRS. aureus Endocarditis and Bactevenia Study GroupDaptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureusN Engl J Med200635565366516914701
   PubMed Web of Science ®Google Scholar
• RandKHHouckHJSynergy of daptomycin with oxacillin and other beta-lactams against methicillin-resistant Staphylococcus aureusAntimicrob Agents Chemother2004482871287515273094
   PubMed Web of Science ®Google Scholar
• SafdarNAndesDCraigWAIn vivo pharmacodynamic activity of daptomycinAntimicrob Agents Chemother200448636814693519
   PubMed Web of Science ®Google Scholar
• ChaRGruczRGJrRybakMJDaptomycin dose-effect relationship against resistant gram-positive organismsAntimicrob Agents Chemother2003471598160312709328
   PubMed Web of Science ®Google Scholar
• SakoulasGEliopoulosGMAlderJEfficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureusAntimicrob Agents Chemother2003471714171812709345
   PubMed Web of Science ®Google Scholar
• JohnAKBaldoniDHaschkeMEfficacy of daptomycin in implant-associated infection due to methicillin-resistant Staphylococcus aureus: importance of combination with rifampinAntimicrob Agents Chemother2009532719272419364845
   PubMed Web of Science ®Google Scholar
• TsujiBTRybakMJShort-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetationsAntimicrob Agents Chemother2005492735274515980344
   PubMed Web of Science ®Google Scholar
• RehmSJBoucherHLevineDDaptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolatesJ Antimicrob Chemother2008621413142118782781
   PubMed Web of Science ®Google Scholar
• LaPlanteKLRybakMJImpact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic modelAntimicrob Agents Chemother2004484665467215561842
   PubMed Web of Science ®Google Scholar
• HanbergerHNilssonLEMallerRIsakssonBPharmacodynamics of daptomycin and vancomycin on Enterococcus faecalis and Staphylococcus aureus demonstrated by studies of initial killing and postantibiotic effect and influence of Ca2+ and albumin on these drugsAntimicrob Agents Chemother199135171017161659305
   PubMed Web of Science ®Google Scholar
• DvorchikBArbeitRDChungJLiuSKnebelWKastrissiosHPopulation pharmacokinetics of daptomycinAntimicrob Agents Chemother2004482799280715273084
   PubMed Web of Science ®Google Scholar
• Cubist Pharmaceuticals IncDaptomycin: full prescribing information Available from: http://www.cubicin.com/pdf/PrescribingInformation.pdfAccessed February 10, 2012
   Google Scholar
• OderoROClevelandKOGelfandMSRhabdomyolysis and acute renal failure associated with the co-administration of daptomycin and an HMG-CoA reductase inhibitorJ Antimicrob Chemother2009631299130019346518
   PubMed Web of Science ®Google Scholar
• WebsterPSOlesonFBJrPatersonDLInteraction of daptomycin with two recombinant thromboplastin reagents leads to falsely prolonged patient prothrombin time/International Normalized Ratio resultsBlood Coagul Fibrinolysis200819323818180613
   PubMed Web of Science ®Google Scholar
• FalagasMERafailidisPIKasiakouSKEffectiveness and nephrotoxicity of colistin monotherapy vs colistin-meropenem combination therapy for multidrug-resistant Gram-negative bacterial infectionsClin Microbiol Infect2006121227123017121631
   PubMed Web of Science ®Google Scholar